Pharmadrug Inc. operates as a specialized pharmaceutical company, primarily dedicated to the exploration, development, and commercialization of controlled substances and naturally derived therapeutic agents. Its portfolio encompasses novel compounds like psychedelics and cannabis, alongside other naturally sourced approved medicines. Beyond its core research and development activities, the firm plays a crucial role in importing and distributing medical cannabis to pharmacies across Germany and the broader European Union. The company also oversees Super Smart, an initiative focused on promoting and exploring the benefits of functional and psilocybin mushrooms. Additionally, Pharmadrug actively engages in researching and enhancing established natural remedies. Significant research collaborations underpin its innovative pipeline, including an agreement with the University of Michigan to assess N, N-dimethyltryptamine's (DMT) role in various conscious states. Another partnership with the Southwest Research Institute is geared towards the non-clinical and clinical manufacturing of cepharanthine. Furthermore, a clinical trial agreement with Johns Hopkins University facilitates a study comparing the acute and enduring psychological and neural effects of DMT against an undisclosed, highly active comparator molecule. Headquartered in Toronto, Canada, the company adopted its current name, Pharmadrug Inc., in October 2019, having previously operated as Aura Health Inc.